A randomized, double‐blind study to compare the efficacy and safety of nalbuphine nasal spray and injectable solution in patients after orthopaedic interventions and traumatological procedures
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16077 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Volodymyr G Tymko und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical company Microkhim, Kyiv, Ukraine. Hauptthemen laut MEDLINE: Nalbuphine, Analgesics, Opioid, Postoperative Pain, Orthopedic Procedures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Aims
Our previous 3‐period crossover study in healthy volunteers comparing the pharmacokinetics of nalbuphine nasal spray Apain with parenteral nalbuphine solution demonstrated high bioavailability of the nasal spray and close similarity of pharmacokinetic profiles after intranasal and intramuscular administration, especially within 30 min postdose. The aim of the present study was a noninferiority assessment of nalbuphine nasal spray vs . intramuscular injection for pain relief in postoperative patients.
Methods
Ninety orthopaedic and traumatology patients were enrolled in this double‐blind, randomized study of the effectiveness and tolerance of a single 10.5 mg dose of nalbuphine nasal spray vs . 10 mg intramuscular injection. The summed pain intensity difference (SPID 0–6 ) calculated using visual analogue scale scores was the primary study endpoint.
Results
Of 90 subjects enrolled, the per‐protocol efficacy population comprised 79 patients; 6 patients in the reference group and 5 patients in the test group were excluded due to remedication. The mean values of study endpoints with 95% confidence interval were as follows in reference and test groups, respectively: SPID 0–6 = 228.08 (205.73–250.43) vs . 248.73 9 (225.83–271.63), time to pain relief onset = 0.28 h (0.25–0.31) vs . 0.27 h (0.25–0.29), duration of analgesia = 5.55 h (5.17–5.93) vs . 5.51 h (5.10–5.92), area under the curve = 119.30 (91.17–147.43) vs . 99.81 (74.52–107.10). No statistically significant differences were revealed.
Conclusion
Nalbuphine nasal spray Apain has been proven to be a safe, noninvasive alternative to intramuscular nalbuphine to relieve severe postoperative pain. Designed for self‐administration and dose‐adjusting, the noncontrolled opioid analgesic nalbuphine spray can be used for patient‐controlled analgesia in out‐of‐hospital, field and home settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical company Microkhim, Kyiv, Ukraine.
- Clinical and Diagnostic Center Pharmbiotest, Kyiv, Ukraine.
- Sytenko Institute of Spine and Joint Pathology National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine.
- Regional Clinical Trauma Hospital, Kharkiv, Ukraine.
ORCID-Profile: Igor E Kuznetsov
Zitieren
APA
Tymko, V. G., Tsapko, G. V., Filipenko, V. A., Khvysiuk, O. M., Kovalova, K. V., & Kuznetsov, I. E. (2024). A randomized, double‐blind study to compare the efficacy and safety of nalbuphine nasal spray and injectable solution in patients after orthopaedic interventions and traumatological procedures. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16077
Vancouver
Tymko VG, Tsapko GV, Filipenko VA, Khvysiuk OM, Kovalova KV, Kuznetsov IE. A randomized, double‐blind study to compare the efficacy and safety of nalbuphine nasal spray and injectable solution in patients after orthopaedic interventions and traumatological procedures. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16077
BibTeX
@article{Tymko2024,
author = {Tymko, Volodymyr G and Tsapko, Grigorii V and Filipenko, Volodymyr A and Khvysiuk, Oleksiy M and Kovalova, Kateryna V and Kuznetsov, Igor E},
title = {A randomized, double‐blind study to compare the efficacy and safety of nalbuphine nasal spray and injectable solution in patients after orthopaedic interventions and traumatological procedures},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16077}
}
EUVIMED